Purpose In this review we describe the general methodology and the results of the international projects, conducted by the Paediatric Rheumatology International Trials Organisation (PRINTO), in collaboration with the Paediatric Rheumatology Collaborative Study Group (PRCSG). The aim of these projects were to identify and validate criteria for the evaluation of response to therapy in clinical trials and in daily clinical practice in patients with the three major paediatric rheumatic diseases (PRD): juvenile idiopathic arthritis (JIA), juvenile dermatomyositis (JDM) and juvenile systemic lupus erythematosus (JSLE). Methods The methodological approach to identify and validate outcome measures can be divided into three main phases: (1) the development of a preliminary core set of measures to evaluate the outcome (e.g. response to therapy, remission criteria, disease activity or damage etc.) through literature review and consensus techniques; (2) a large-scale data collection for a prospectively evidence-based validation of the preliminary findings; (3) the final development of a validated criteria for the evaluation of the outcome. Results The core sets for three diseases included domains that are common to all diseases (physician's global assessment of disease activity; parent's global assessment of the overall patient's well-being; disability and/or healthrelated quality of life) plus additional domains that are specific for each disease. In order to be classified as a responder to a given treatment, a patient should demonstrate a different minimum level of improvement (≥30% in JIA, ≥20% in JDM, and ≥50% in JSLE) with no more than one of the remaining variables worsening by more than 30%. Conclusions The proposed core sets and definitions of improvement incorporate clinically meaningful change in a composite endpoint for the evaluation of global response to therapy in the major PRD. The definitions are proposed for use in PRD clinical trials and may help physicians to decide if a child has responded adequately to therapy.
Introduction
Performing clinical trials involving paediatric patients with rheumatic diseases (PRD) is made difficult by the small number of eligible patients, the heterogeneity of disease manifestations and the lack of standardised criteria to assess clinical response. This situation has improved over the last 10 years thanks to several factors: (1) the implementation of adequate U.S. and European paediatric legislation [1] [2] [3] [4] , (2) the existence of two large not-for-profit networks which have facilitated successful trial completion, namely the Paediatric Rheumatology Trials Organisation (PRINTO at www.printo.it or www.pediatric-rheumatology.printo.it) [5] and the Paediatric Rheumatology Collaborative Study Group (PRCSG at www.prcsg.org) and (3) the availability of standardised and validated criteria for the evaluation of response to therapy in for the PRD.
Indeed, the availability of standardised criteria would provide a common basis for comparing different treatment options, permit study and statistical comparison of patients with different disease manifestations and facilitate comparisons of different clinical trials with meta-analysis.
The aim of this paper was to review the general methodology and present the criteria used to define response to therapy in the three major PRD: juvenile idiopathic arthritis (JIA), juvenile systemic lupus erythematosus (JSLE) and juvenile dermatomyositis (JDM).
Methodological aspects
One of the specific problems encountered by researchers studying PRD is the lack of objective measures that can be reliably used to evaluate response to therapy. Consequently, there is an urgent need to use surrogate clinical and laboratory markers to assess disease activity level.
In general. the methodological approach to solve such problems can be categorised into three main phases: (1) the development of a preliminary core set of measures to evaluate the outcome under consideration (e.g. response to therapy, remission criteria, disease activity or damage etc.) through a literature review and consensus techniques; (2) a large-scale data collection for a prospectively evidence-based validation of the preliminary findings; (3) the final development of validated criteria for the evaluation of the outcome under consideration.
Consensus methodologies
The use of well-recognised consensus formation methodologies specifically designed to assimilate judgements from a group of experts in a particular field is considered necessary whenever there are no objective measures to properly assess the outcome. The two major recognised techniques are the Delphi Technique and the Nominal Group Technique [6] [7] [8] . In brief, the Delphi Technique utilises a series of well-defined questionnaire based-surveys while the Nominal Group Technique is a structured face-to-face meeting designed to facilitate reaching consensus on the topic of study. Consensus formation techniques require that each step is based on the results of the previous steps. These techniques have been used to develop the outcome measures of several chronic rheumatic diseases, including JIA [9, 10] , adult rheumatoid arthritis [11] , adult-onset SLE [12, 13] and idiopathic inflammatory myopathies [14] [15] [16] as well as JSLE [17] [18] [19] and JDM [20] .
What is a core set of measures and why it is needed (e.g. in paediatric rheumatology)
The intention of the core set is to provide a minimum list of domains/variables to cover all (or most) aspects of the disease and also to function as a minimum list to be always reported in future studies. In paediatric rheumatology we lack true outcome measures (e.g. death, pneumonitis, glucose etc.) therefore, there is a need for surrogate markers for the evaluation of the outcome under consideration (in the following paragraph referred to as outcome) from different perspectives.
Phase 1. The preliminary core set selection In this initial phase, after a carefully literature review, it is essential to prepare a mailing survey of people potentially interested in participating in a sequential questionnaire-based e-mail survey using the Delphi Technique. The mailing list can contain up to several hundreds of people [17] and constitutes the proper denominator against which to evaluate the success of the survey that usually requires a response rate of 70-80%. The first questionnaire is generic and is used to evaluate, in broad terms, which variables are to be used in routine clinical practice to assess the outcome. The data from the first survey are then analysed and collated to prepare the second survey in which the content is more specific. In this second survey, responders can be asked to concentrate only on those variables selected by a minimum threshold of people in the first survey, to select the most important variable (e.g. usually no more than 10) and to rank these in order of importance. Other surveys-if necessary-can be added.
The results of the mailing survey are usually not sufficient to select the final list of variables to be used. In this case, the results of the survey, along with a proper literature search, can be used to convene a nominal group technique consensus conference among a restricted number of people whose goal is indeed to reach the consensus (80% required) on the measures to be included in the preliminary core set. The number of persons per table (maximum 2-3 tables) should usually not be greater than ten.
Phase 2. The prospective validation of the preliminary core set(s) The aim of the second phase is to formally validate the preliminary consensus-based core sets through a prospective, large-scale data collection among the members. The objective of this phase is to further define and validate the preliminary core set variables in order to document the outcome. A detailed protocol that lists the proper inclusion/exclusion criteria needs to be set up in order to collect data ideally in a prospective fashion. Data collection should try to mimic what is usually performed in a clinical trial, with a baseline assessment at the time of the starting treatment and a final assessment after a certain follow-up period. Data collection should include all variables in the preliminary consensus-based core set, plus all additional variables that are deemed necessary in the analysis phase, such as demographic, clinical and laboratory data, treatment options etc. According to the OMERACT filter for outcome measures in rheumatology [21, 22] , the main purposes of the validation phase are to evaluate the following properties [17] : feasibility (brevity, simplicity, easy scoring etc.); face and content validity (variables easiest to use and most credible); responsiveness (ability of each variable to detect clinically important change between baseline and 6 months) measured through the standardised response mean (SRM) [23] ; discriminative ability (ability to discriminate patients who improved from those who did not); convergent construct validity to examine whether the construct in question is related to other measures in a manner consistent with a priori prediction; collinearity (or redundancy); optionally, internal consistency by Cronbach's coefficient alpha [24] . Finally, the association between the core measures and response to therapy as judged by the attending physician can be evaluated through a multivariate logistic regression analysis.
Phase 3. The definition of improvement At the end of the data collection process, the related analysis should be presented in another nominal group technique consensus based meeting to a panel of experts (or experienced clinicians) knowledgeable about the outcome. The purposes of the meeting is to discuss the statistical properties of the measures and confirm/refine the final core set of measures. Another important goal is to establish the amount of change over time for the variables included in the core set in order to properly quantify the outcome under consideration (e.g. criteria for response to therapy). The meeting should therefore properly define the final core set of endpoints, using a combination of statistical criteria and consensus formation techniques.
Examples in paediatric rheumatology
The core sets of measures for JIA, JSLE and JDM The domains and the suggested variable for measuring each domain for JIA [9, 10] , JSLE [17] [18] [19] and JDM [20] are presented in Table 1 . The suggested variables include the measures which at the present time have the better statistical properties; however, in the future, other measures appearing in the literature may replace the existing ones if they will demonstrate better statistical properties.
The domains are divided into the common domains (to be used for all 3 diseases) and specific domains.
The common domains for JIA, JSLE and JDM include two global assessments, namely, one by the physician and one by the parents/patients, usually measured with a 10-cm visual analogue scale (VAS) or a 21 circle VAS [25] . A measure of functional ability (disability) using the Childhood Health Assessment Questionnaire (CHAQ) [26] [27] [28] or the Juvenile Arthritis Functionality Scale (JAFS) [29] and/or a quality of life measures is also considered, usually through the Physical Summary score (PhS) of the Child Health Questionnaire (CHQ) [28, 30] or the Paediatric Rheumatology Quality of Life Scale (PRQL) [31] .
Disease-specific domains for JIA include two measures of joint involvement (the number of joints with active arthritis and the number of joints with limited range of motion) [32] [33] [34] [35] and an index of inflammation. For systemic JIA children, an absence of spiking fever (≤38°C during the week preceding the evaluation) is an additional requirement.
The JSLE-specific domains include a global disease activity assessment, either by the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) [36] , the Systemic Lupus Activity Measures (SLAM) [37] or the European Consensus Lupus Activity Measurement (ECLAM) [38, 39] , and a measure of kidney involvement (24-hour proteinuria).
Disease-specific domains for JDM include a measure of muscle strength as assessed by the Childhood Myositis Assessment Scale (CMAS) [40] [41] [42] or the Manual Muscle Testing (MMT) [43] , a global disease activity assessment through the Disease Activity Score (DAS) [44] or, alternatively, the Myositis Disease Activity Assessment (MDAA, an instrument [45] that combines two partially overlapping tools named the Myositis Disease Activity Assessment Visual Analogue Scale (MYOACT) and the Myositis Intention to Treat Activity Index A-E version (MITAX) [45] .
Overall, the measures include in the three core sets were found to be feasible and not redundant, to have good construct validity, discriminative ability, internal consistency, were responsiveness to clinically important change in disease activity, and were associated strongly with treatment outcome [9, 10, [17] [18] [19] [20] .
The definition of improvement in JIA, JSLE and JDM The definitions of improvement to be used as the main outcome in trials involving patients with JIA [9, 10] , JSLE [17] [18] [19] and JDM [20] are given in Table 2 . The definitions require a minimum level of improvement (30% in JIA, 50% in JSLE and 20% in JDM) in x number of the variables included in the core sets (Table 1) , with no more than one of the remaining variables worsened by more than 30%. For example, the JIA definition of improvement for JIA is at least 30% improvement from baseline in three of any six variables in the core set, with no more than one of the remaining variables worsening by more than 30%. For trials involving patients with systemic JIA, absence of spiking fever (≤38°C during the week preceding the evaluation) is also required. The minimum level of improvement has to be reported in all trials as the primary outcome, but researchers should also report more a stringent definition of improvement (50, 70, 90 or 100%) as the secondary outcome in the trial results.
The definition of flare for JIA An innovative trial design in JIA is the use of the socalled randomised, double-blind controlled, withdrawal design. This study design was proposed by Giannini and Lovell for use in paediatric rheumatology studies [46] based on the rational of avoiding the placebo arm for children with chronic conditions when alternative effective treatments are available. Eligible children are treated in an open label fashion with the experimental therapy to be tested in the trial for a few months after which responders (typically those demonstrating American College of Rheumatology (ACR) paediatric 30 response criteria) are randomised in a double-blind fashion either to continue the experimental therapy or to switch to placebo. In this segment of the study, called the doubleblind withdrawal phase, patients who demonstrate a predefined definition of disease worsening (e.g. "flare") are withdrawn from the double-blind withdrawal phase of the trial and re-treated with the experimental therapy in an open label fashion. A specific characteristic of this trial design is, therefore, the need to have a proper definition of flare to be used in the double-blind withdrawal phase. The flare definition currently used in JIA is essentially the inverse of the ACR paediatric 30 response criteria [47] . This definition requires that there be at least a 30% The overall domain is reported In the first column; the suggested variables to measure each specific domain in the three diseases is reported in the following columns worsening in three of the six JIA core set parameters, with no more than one improving by more than 30%. In addition, there are a number of contingencies requiring that if either the number of active joints or the number of joints with a limitation of motion are used in the flare definition, there must be at least a two joint increase in the number of active joints or those with limited range of motion, respectively. Also, if the physical or parent global scales are used in the flare definition, a worsening ≥2 cm (on a 0-10 cm scale) is required. Additionally, for systemic JIA patients only, the reappearance of spiking fever (>38°C, lasting for at least 2 days in the week preceding the evaluation) not due to infections would signify that a flare has occurred. These flares criteria have been validated and shown to be sensitive in terms of limiting the degree of the worsening patient symptoms to avoid potential damage in subjects randomised to placebo and those children losing response to the experimental agent.
The definition of remission for JIA An additional definition available for JIA is the Childhood Arthritis and Rheumatology Research Alliance (CARRA)/ PRINTO/Paediatric Rheumatology Collaborative Study Group (PRCSG) criteria for inactive disease [48] that requires the absence of active arthritis, fever, rash, serositis, splenomegaly or generalised lymphadenopathy attributable to JIA, active uveitis, normal erythrocyte sedimentation rate or C-reactive protein and a physician's global assessment of disease activity rated at the best score possible for the instrument used. The presence of 6 continuous months of inactive disease defines clinical remission on medication, while 12 months of inactive disease with the patient off all anti-arthritis medications defines clinical remission off medication.
Final remarks and future perspective
The criteria for the evaluation of response to therapy in PRD were designed to ensure that certain minimum criteria/ standards are applied to observational and randomised controlled trials and to facilitate comparison with future meta-analysis. They can also assist in standardising outcome measurements in daily clinical practice. The core set includes the indication of instruments that can be used to assess each domain. However, the specific instrument can be modified or integrated whenever new valid tools or better laboratory indicators are developed to measure a particular domain or become more suitable for use in the paediatric group of patients. The proposed core sets also combine aspects of the disease that can be measured easily in clinical practice, and indeed only measures that can be assessed reliably world-wide were included.
In conclusion, the proposed core sets and definitions of improvement incorporate clinically meaningful change in a composite endpoint for the evaluation of global response to therapy in the major PRD. The definitions are proposed for use in PRD clinical trials and may help physicians to decide if a child has responded adequately to therapy. Table 2 Definitions by which to evaluate response to therapy in JIA, JSLE and JDM JIA JSLE JDM Definition of improvement At least 30% a improvement from baseline in 3 of any 6 variables in the core set-with no more than one of the remaining variables worsening by more than 30%.
At least 50% a improvement from baseline in any 2 among the 5 core set measureswith no more than 1 of the remaining worsening by more than 30%.
At least 20%
a improvement from baseline in 3 of any 6 core set domains-with no more than 1 of the remaining worsening by more than 30%, which cannot be muscle strength For systemic JIA, absence of spiking fever (≤38°C during the week preceding the evaluation) is also required Definition of flare: At least a 30% worsening in 3 of the 6 JIA core set parameters, with no more than one improving by more than 30%. 
